SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Stryker Corporation (SYK) Bank of America Securities 2025 Global Healthcare Conference (Transcript)
Stryker Corporation (NYSE:SYK ) Bank of America Securities 2025 Global Healthcare Conference May 13, 2025 4:40 PM ET Company Participants Preston Wells - Chief Financial Officer Jason Beach - Vice President, Finance and Investor Relations Conference Call Participants Travis Steed - Bank of America Travis Steed [abrupt start] the Bank of America medical device analyst and continuing our day of Medtech conversations. Next up we've got Stryker Corporation, Preston Wells, newly appointed CFO; and Jason Beach, VP of Finance and IR.
Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold)
I am downgrading Stryker Corporation to a Hold rating with a fair value of $380 per share, despite strong performance and growth prospects. Stryker's Mako spine and shoulder applications are set to launch soon, potentially boosting its orthopedics and spine businesses. Stryker posted robust Q1 results with 10.1% organic revenue growth and 13.6% adjusted EPS growth, driven by strong topline and margin improvements.
Stryker (SYK) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.
Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript
Stryker Corporation (NYSE:SYK ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Preston Wells - Vice President, Chief Financial Officer Conference Call Participants Marcus Robert - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Ryan Zimmerman - BTIG Travis Steed - Bank of America Vijay Kumar - Evercore ISI David Roman - Goldman Sachs Philip Chickering - Deutsche Bank Matthew Miksic - Barclays Patrick Wood - Morgan Stanley Shagun Singh - RBC Mike Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Danielle Antalffy - UBS Matt Taylor - Jefferies Operator Welcome to the First Quarter 2025 Stryker Earnings Call. My name is Luke and I'll be your operator for today's call.
Stryker (SYK) Surpasses Q1 Earnings and Revenue Estimates
Stryker (SYK) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.73 per share. This compares to earnings of $2.50 per share a year ago.
Strong Segmental Performance to Drive Stryker's Q1 Earnings?
SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Gear Up for Stryker (SYK) Q1 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Stryker (SYK) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Stryker (SYK) Reports Next Week: Wall Street Expects Earnings Growth
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stryker Unveils Next-Generation Mako SmartRobotics but Stock Falls
SYK unveils next-gen Mako SmartRobotics, revolutionizing hip, knee and spine surgeries with greater precision and first-to-market robotic hip revision technology.
